La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

2cureX Salute del bilancio

Salute finanziaria criteri di controllo 4/6

2cureX ha un patrimonio netto totale di SEK12.1M e un debito totale di SEK0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente SEK16.3M e SEK4.2M.

Informazioni chiave

Rapporto debito/patrimonio netto

SEK 0

Debito

Indice di copertura degli interessi	n/a
Contanti	SEK 13.40m
Patrimonio netto	SEK 12.08m
Totale passività	SEK 4.20m
Totale attività	SEK 16.28m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

Jun 03

2cureX (STO:2CUREX) Is In A Good Position To Deliver On Growth Plans

Jan 06

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

Sep 23

We're Interested To See How 2cureX (STO:2CUREX) Uses Its Cash Hoard To Grow

Jun 02

Shareholders Of 2cureX (STO:2CUREX) Must Be Happy With Their 280% Total Return

Feb 18

How Does 2cureX's (STO:2CUREX) CEO Salary Compare to Peers?

Nov 29

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( SEK15.6M ) di 2CUREX superano le sue passività a breve termine ( SEK4.1M ).

Passività a lungo termine: Le attività a breve termine di 2CUREX ( SEK15.6M ) superano le sue passività a lungo termine ( SEK51.0K ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 2CUREX è esente da debiti.

Riduzione del debito: 2CUREX non ha avuto debiti negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: 2CUREX ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: 2CUREX ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 37.5 % ogni anno

2cureX Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

2cureX (STO:2CUREX) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

We're Interested To See How 2cureX (STO:2CUREX) Uses Its Cash Hoard To Grow

Recent updates

2cureX AB (publ) to Report Fiscal Year 2024 Final Results on Apr 24, 2025

2cureX AB (publ) Announces CEO Changes

2cureX AB (publ) to Report Q4, 2024 Results on Feb 20, 2025

No independent directors

2curex AB (publ) Elects Grith Hagel as a New Board Member

Full year 2023 earnings released: kr1.75 loss per share (vs kr1.69 loss in FY 2022)

2cureX AB (publ), Annual General Meeting, May 23, 2024

2cureX AB (publ) to Report Q2, 2024 Results on Aug 22, 2024

2cureX AB (publ) Receives Ethical Approval for HIPEC Clinical Trial

Third quarter 2023 earnings released: kr0.58 loss per share (vs kr0.47 loss in 3Q 2022)

2Curex AB (Publ) Appoints Tonni Bülow-Nielsen as Board Member and Chairman

New minor risk - Share price stability

2curex Launches Its First Two IndiTreat® Products Ce-Marked Under the New Ivd Regulation

New major risk - Financial position

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.45 loss in 1Q 2022)

Chief Executive Officer recently bought kr136k worth of stock

Chief Executive Officer recently bought kr136k worth of stock

Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021)

Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021)

2cureX AB (publ) Appoints Michel Klimkeit to Board of Director

2cureX AB (publ) to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2022 earnings released: kr0.47 loss per share (vs kr0.31 loss in 3Q 2021)

High number of new and inexperienced directors

2cureX AB (publ), Annual General Meeting, May 25, 2023

2cureX Announces Board Change

Chief Executive Officer recently bought kr84k worth of stock

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

2cureX AB (publ) Presents Inditreat® Clinical Results At the Society for Functional Precision Medicine

High number of new and inexperienced directors

Manuel Fernández Joins 2cureX as Director of Quality Assurance and Regulatory Affairs

2cureX AB (publ) Announces Management Changes

2cureX (STO:2CUREX) Is In A Good Position To Deliver On Growth Plans

2cureX Launches IndiTreat mCRC Start Test to Guide First Line Treatment

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

2cureX Announces New Development of the IndiTreat Technology Allows Prediction of Response to Anti-Angiogenic Drugs in Colorectal Cancer

High number of new and inexperienced directors

We're Interested To See How 2cureX (STO:2CUREX) Uses Its Cash Hoard To Grow

2Curex AB (Publ) Clinical Partner, University Hospital Vejle, Presents Positive Results of Thnditreat®-Guided Clinicaical Trial in Third Line Metastatic Colorectal Cancer At the Asco 2021 Annual Meeting

Co-Founder exercised options to buy kr7.6m worth of stock.

2cureX AB (publ) Announces Clinical Trial of Inditreat®-Guided Treatment of Metastatic Colorectal Cancer

2cureX AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Shareholders Of 2cureX (STO:2CUREX) Must Be Happy With Their 280% Total Return

2cureX AB's IndiTreat® Selected to Prestigious Multinational Ovarian Cancer Project

New 90-day high: kr22.60

Chief Financial Officer has left the company

2cureX Appoints Kenneth Graabek Johansen as New CFO, Effective 1 February 2021

2cureX Announces Last Patient Treated in the World's First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment

New 90-day high: kr17.65

2cureX Announces Management Changes

2cureX AB (publ), Annual General Meeting, May 27, 2021

How Does 2cureX's (STO:2CUREX) CEO Salary Compare to Peers?

New 90-day low: kr16.25

2cureX Announces Last Patient Successfully Enrolled in the Worlds First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment

New 90-day low: kr17.30

2cureX launches world's first CE-marked microtumor test service

New 90-day high - kr22.50

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane